Superworth

RxSight price to sales ratio RXST

Market value divided by revenue over the last twelve months, since 2022.

Today, Nov 2, 2026
1.6×
5-year median
10.5×
Against its 5-year history
2nd
percentile: 0 is its lowest day, 100 its highest
5-year range
1.5× to 25.7×
Peer median
1.3×

RxSight's price to sales ratio is 1.6× as of Nov 2, 2026.

That is below its 5-year median of 10.5×, lower than on 98% of days in the last 5 years.

Over that time it ranged from 1.5× in Oct 2026 to 25.7× in Feb 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 1.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.6×1.5×3.0×
20253.2×2.0×11.3×
202410.8×10.6×25.7×
202318.9×8.6×19.7×
20228.5×7.6×16.5×

Against its peers

Companies in Medical - Instruments & Supplies nearest RxSight's size, closest first, today.

Where RxSight ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on RxSight

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.